Point72 Asset Management
CADL icon

Point72 Asset Management’s Candel Therapeutics CADL Stock Holding History

Point72 Asset Management’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$525K Buy
+107,211
New +$583K ﹤0.01% 3096
2022
Q4 		– Sell
-403,131
Closed -$1.27M – 1527
2022
Q3 		$1.27M Sell
403,131
-339,951
-46% -$1.15M 0.01% 1014
2022
Q2 		$2.41M Buy
+743,082
New +$2.98M 0.01% 894

Other funds holding CADL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Point72 Asset Management's CADL Position: Q1 2026 in Review

Point72 Asset Management opened a new position in Candel Therapeutics (CADL) in Q1 2026: 107,211 shares worth $525K. The stake represents ﹤0.01% of the portfolio and ranks #3096 among its holdings. This is a return to the name: Point72 Asset Management previously reported a position in CADL as recently as Q3 2022.

Point72 Asset Management first reported a position in CADL in Q2 2022 and has held it in 3 quarters since. The position peaked at $2.41M in Q2 2022. 114 funds tracked by Wall St. Rank hold CADL as of Q1 2026.

  • Point72 Asset Management held 107,211 shares of Candel Therapeutics worth $525K as of Q1 2026.
  • Candel Therapeutics was a new Point72 Asset Management position in Q1 2026.
  • Candel Therapeutics made up ﹤0.01% of Point72 Asset Management's portfolio in Q1 2026, its #3096 holding.
  • Point72 Asset Management first reported a position in Candel Therapeutics in Q2 2022 and has held it in 3 quarters since.
  • Point72 Asset Management's Candel Therapeutics position peaked at $2.41M in Q2 2022.
  • 114 funds tracked by Wall St. Rank held Candel Therapeutics as of Q1 2026.

Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.